Approved: Daiichi Sanyo’s edoxaban

Tuesday, April 26, 2011 01:28 PM

Japan-based Daiichi Sankyo has received marketing approval by the Japanese Ministry of Health, Labor and Welfare for its anticoagulant edoxaban, according to Pharma Times.  

Edoxaban, a direct factor Xa inhibitor taken once a day has been approved for the prevention of venous thromboembolism (VTE) in patients with total knee and hip arthroplasty and hip fracture surgery.  It will be sold as Lixiana.

Joji Nakayama, Daiichi Sankyo chief executive, said the company thinks the drug “will make a great contribution to VTE prevention after major orthopedic surgery,” noting that Daiichi Sankyo is researching options for the drug for “several other indications.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs